{"name":"Institut Claudius Regaud","slug":"institut-claudius-regaud","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"PRRT with 177Lu-DOTATATE","genericName":"PRRT with 177Lu-DOTATATE","slug":"prrt-with-177lu-dotatate","indication":"Other","status":"phase_1"},{"name":"Pharmacokinetics blood samples","genericName":"Pharmacokinetics blood samples","slug":"pharmacokinetics-blood-samples","indication":"Other","status":"marketed"},{"name":"Tamoxifen, Letrozole , Anastrozole, Exemestane","genericName":"Tamoxifen, Letrozole , Anastrozole, Exemestane","slug":"tamoxifen-letrozole-anastrozole-exemestane","indication":"Other","status":"marketed"},{"name":"Zarnestra","genericName":"Zarnestra","slug":"zarnestra","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tamoxifen, Letrozole, Anastrozole or Exemestane","genericName":"Tamoxifen, Letrozole, Anastrozole or Exemestane","slug":"tamoxifen-letrozole-anastrozole-or-exemestane","indication":"Hormone receptor-positive breast cancer, adjuvant treatment","status":"marketed"}]}],"pipeline":[{"name":"PRRT with 177Lu-DOTATATE","genericName":"PRRT with 177Lu-DOTATATE","slug":"prrt-with-177lu-dotatate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pharmacokinetics blood samples","genericName":"Pharmacokinetics blood samples","slug":"pharmacokinetics-blood-samples","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Tamoxifen, Letrozole , Anastrozole, Exemestane","genericName":"Tamoxifen, Letrozole , Anastrozole, Exemestane","slug":"tamoxifen-letrozole-anastrozole-exemestane","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamoxifen, Letrozole, Anastrozole or Exemestane","genericName":"Tamoxifen, Letrozole, Anastrozole or Exemestane","slug":"tamoxifen-letrozole-anastrozole-or-exemestane","phase":"marketed","mechanism":"These drugs block estrogen signaling in breast cancer cells, either by directly antagonizing the estrogen receptor (tamoxifen) or by inhibiting aromatase to reduce estrogen production (letrozole, anastrozole, exemestane).","indications":["Hormone receptor-positive breast cancer, adjuvant treatment","Hormone receptor-positive breast cancer, metastatic","Breast cancer prevention in high-risk women (tamoxifen)"],"catalyst":""},{"name":"Zarnestra","genericName":"Zarnestra","slug":"zarnestra","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":1,"marketed":3,"discontinued":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}